NDA 022536 · Fresenius Kabi USA
Indomethacin
Indomethacin · Injection · Nonsteroidal Anti-inflammatory Drug
Last checked: Nov 20, 2026Latest source record: Dec 21, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2010
Mar 17, 2010
Approved uses
1
Original approval plus efficacy supplements
Registered trials
557
100 Phase 3, 44 recruiting
FAERS reports
11,101
9,017 serious, 1,293 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jan 19, 2026.
Indomethacin for Injection is indicated to close a hemodynamically significant patent ductus arteriosus in premature infants weighing between 500 and 1,750 g when 48 hours usual medical management (e.g., fluid restriction, diuretics, digitalis, respiratory support, etc.) is ineffective. Clear-cut clinical evidence of a hemodynamically significant patent ductus arteriosus should be present, such as respiratory distress, a continuous murmur, a hyperactive precordium, cardiomegaly, or pulmonary plethora on chest x-ray. Indomethacin for Injection is a cardiovascular drug indicated: • To close a hemodynamically significant patent ductus arteriosus in premature infants weighing between 500 and 1,750 g. ( 1 )
Mechanism: Although the exact mechanism of action through which indomethacin causes closure of a patent ductus arteriosus is not known, it is believed to be through inhibition of prostaglandin synthesis.
Therapeutic areas: Pain and anesthesia
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 17, 2010 Original approval · Type 5 - New Formulation or New Manufacturer Summary ReviewLabelReview
1 products under this application
- INDOMETHACIN · INDOMETHACIN EQ 1MG BASE/VIAL · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Indomethacin" as an intervention, any sponsor and status, largest first.
- Rectal Indomethacin and Oral Tacrolimus Versus Combination to Prevent Post-ERCP PancreatitisPivotal-lookingRecruiting
Johns Hopkins UniversityAcademic, hospital or other
NCT05252754 · 4,874 participants (planned) · Start Jan 18, 2023 · Primary completion Dec 2026
Drug: Tacrolimus capsule; Placebo and 1 more · For: Post-ERCP Acute Pancreatitis
Sites: Baltimore, Maryland; Hyderabad, India; Kolkata, India · 5 sites in all
- Indomethacin vs Diclofenac for Preventing PEPPivotal-lookingRecruiting
Air Force Military Medical University, ChinaAcademic, hospital or other
NCT07071441 · 4,050 participants (planned) · Start Jun 1, 2025 · Primary completion Dec 31, 2026
Drug: Indomethacin 100 MG; Diclofenac 100mg · For: ERCP; Pancreatitis; Non-steroidal Anti-inflammatory (NSAID) and 2 more
Sites: Beijing, China; Chongqing, China; Xiamen, China · 20 sites in all
- Effect of Papillary Epinephrine Spraying on Post-ERCP Pancreatitis in Patients Received Rectal IndomethacinPivotal-lookingTerminated
Air Force Military Medical University, ChinaAcademic, hospital or other
NCT03057769 · 3,300 participants · Start Feb 1, 2017 · Primary completion Oct 26, 2017
Drug: Papillary epinephrine spraying; Papillary saline spraying and 1 more · For: Pancreatitis; Endoscopic Retrograde Cholangiopancreatography
Sites: Xiamen, China; Lanzhou, China; Ankang, China · 10 sites in all
- Rectal Indomethacin Versus Rectal Indomethacin and Sublingual Nitrate for PEP PreventionPivotal-lookingStatus unknown
Air Force Military Medical University, ChinaAcademic, hospital or other
NCT04425993 · 2,700 participants · Start Jul 1, 2020 · Primary completion May 30, 2022
Drug: Isosorbide Dinitrate 5 MG; Indomethacin 100 MG and 2 more · For: Post-ERCP Acute Pancreatitis
Sites: Xiamen, China; Lanzhou, China; Xi'an, China · 4 sites in all
- Oral Resveratrol to Prevent Post-ERCP PancreatitisPivotal-lookingStatus unknown
First Affiliated Hospital Xi'an Jiaotong UniversityAcademic, hospital or other
NCT02947932 · 2,700 participants (planned) · Start Dec 2016 · Primary completion Mar 2018
Drug: Resveratrol; Indomethacin · For: Pancreatitis, Acute; Gastrointestinal Disease
- COX-2 Inhibitor to Prevent Post-ERCP PancreatitisPivotal-lookingStatus unknown
First Affiliated Hospital Xi'an Jiaotong UniversityAcademic, hospital or other
NCT02964403 · 2,700 participants (planned) · Start Dec 2016 · Primary completion Feb 2018
Drug: Cox-2; Indomethacin · For: Pancreatitis, Acute
- Rectal Indomethacin to Prevent Post-ERCP PancreatitisPivotal-lookingCompleted
Air Force Military Medical University, ChinaAcademic, hospital or other
NCT02002650 · 2,600 participants · Start Dec 2013 · Primary completion Nov 2015
Drug: Pre-ERCP rectal Indomethacin; Post-operational Rectal Indomethacin · For: Post-ERCP Acute Pancreatitis
Sites: Lanzhou, China; Yinchuan, China; Xi'an, China · 6 sites in all
- Comparative Effectiveness Between Indomethacin and Pancreatic Stenting in the Prevention of Post ERCP PancreatitisPivotal-lookingRecruiting
Chinese University of Hong KongAcademic, hospital or other
NCT03713879 · 1,734 participants (planned) · Start Mar 21, 2019 · Primary completion May 31, 2028
Drug: Indomethacin · For: Post ERCP Pancreatitis
Sites: Xi'an, China; Shanghai, China; Tianjin, China · 7 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective1,316
- fatigue1,063
- headache978
- off label use968
- arthralgia957
- pain851
- nausea840
- diarrhoea837
- dizziness805
- vomiting689
- dyspnoea681
- asthenia599
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 218 |
| 2005 | 264 |
| 2006 | 278 |
| 2007 | 257 |
| 2008 | 266 |
| 2009 | 307 |
| 2010 | 270 |
| 2011 | 371 |
| 2012 | 458 |
| 2013 | 314 |
| 2014 | 280 |
| 2015 | 385 |
| 2016 | 540 |
| 2017 | 466 |
| 2018 | 649 |
| 2019 | 707 |
| 2020 | 583 |
| 2021 | 716 |
| 2022 | 981 |
| 2023 | 843 |
| 2024 | 873 |
| 2025 | 732 |
| 2026 | 342 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Indomethacin* (Indomethacin)
2024 spending
$3.6M
Beneficiaries
124,276
247,264 claims
Per beneficiary
$29
$0.26 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $3,836,873 |
| 2021 | $3,515,006 |
| 2022 | $3,425,921 |
| 2023 | $3,235,993 |
| 2024 | $3,559,363 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Indomethacin with or without prophylactic pancreatic stent placement to prevent pancreatitis after ERCP: a randomised non-inferiority trial.
Elmunzer BJ, Foster LD, Serrano J, et al. · Lancet 2024 · Randomized Controlled Trial, Equivalence Trial
- Rectal diclofenac versus indomethacin for prevention of post-ERCP pancreatitis (DIPPP): a multicentre, double-blind, randomised, controlled trial.
Kang X, Xia M, Wang J, et al. · Gut 2025 · Multicenter Study, Randomized Controlled Trial
- Indomethacin for intracranial hypertension secondary to severe traumatic brain injury in adults.
Martín-Saborido C, López-Alcalde J, Ciapponi A, et al. · Cochrane Database Syst Rev 2019 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Furosemide in indomethacin-treated infants--systematic review and meta-analysis.
Brion LP, Campbell DE · Pediatr Nephrol 1999 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Indomethacin for symptomatic patent ductus arteriosus in preterm infants.
Evans P, O'Reilly D, Flyer JN, et al. · Cochrane Database Syst Rev 2021 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Efficacy and Costs of Three Pharmacotherapies for Patent Ductus Arteriosus Closure in Premature Infants.
Vidavalur R · Paediatr Drugs 2022 · Meta-Analysis, Systematic Review
Sponsor: Fresenius Kabi USA
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.